DOCSLIB.ORG

Exome Sequencing Enhanced Package Department of Pathology and Laboratory Medicine Feb 2012 UCLA Molecular Diagnostics Laboratories Page:1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Exome Sequencing Enhanced Package Department of Pathology and Laboratory Medicine Feb 2012 UCLA Molecular Diagnostics Laboratories Page:1 UCLA Health System Clinical Exome Sequencing Enhanced Package Department of Pathology and Laboratory Medicine Feb 2012 UCLA Molecular Diagnostics Laboratories Page:1 Gene_Symbol Total_coding_bp %_bp_>=10X Associated_Disease(OMIM) MARC1 1093 80% . MARCH1 1005 100% . MARC2 1797 92% . MARCH3 802 100% . MARCH4 1249 99% . MARCH5 861 96% . MARCH6 2907 100% . MARCH7 2161 100% . MARCH8 900 100% . MARCH9 1057 73% . MARCH10 2467 100% . MARCH11 1225 56% . SEPT1 1148 100% . SEPT2 1341 100% . SEPT3 1175 100% . SEPT4 1848 96% . SEPT5 1250 94% . SEPT6 1440 96% . SEPT7 1417 96% . SEPT8 1659 98% . SEPT9 2290 96% Hereditary Neuralgic Amyotrophy SEPT10 1605 98% . SEPT11 1334 98% . SEPT12 1113 100% . SEPT14 1335 100% . SEP15 518 100% . DEC1 229 100% . A1BG 1626 82% . A1CF 1956 100% . A2LD1 466 42% . A2M 4569 100% . A2ML1 4505 100% . UCLA Health System Clinical Exome Sequencing Enhanced Package Department of Pathology and Laboratory Medicine Feb 2012 UCLA Molecular Diagnostics Laboratories Page:2 Gene_Symbol Total_coding_bp %_bp_>=10X Associated_Disease(OMIM) A4GALT 1066 100% . A4GNT 1031 100% . AAAS 1705 100% Achalasia‐Addisonianism‐Alacrima Syndrome AACS 2091 94% . AADAC 1232 100% . AADACL2 1226 100% . AADACL3 1073 100% . AADACL4 1240 100% . AADAT 1342 97% . AAGAB 988 100% . AAK1 3095 100% . AAMP 1422 100% . AANAT 637 93% . AARS 3059 100% Charcot‐Marie‐Tooth Neuropathy Type 2 AARS 3059 100% Charcot‐Marie‐Tooth Neuropathy Type 2N AARS2 3050 100% . AARSD1 1902 98% . AASDH 3391 100% . AASDHPPT 954 100% . AASS 2873 100% Hyperlysinemia AATF 1731 99% . AATK 4181 78% . ABAT 1563 100% GABA‐Transaminase Deficiency ABCA1 6991 100% ABCA1‐Associated Familial High Density Lipoprotein Deficiency ABCA1 6991 100% Familial High Density Lipoprotein Deficiency ABCA1 6991 100% Tangier Disease ABCA10 4780 100% . ABCA12 8035 100% ABCA12‐Related Autosomal Recessive Congenital Ichthyosis ABCA12 8035 100% Autosomal Recessive Congenital Ichthyosis ABCA12 8035 100% Harlequin Ichthyosis ABCA13 15482 99% . ABCA2 7889 95% . UCLA Health System Clinical Exome Sequencing Enhanced Package Department of Pathology and Laboratory Medicine Feb 2012 UCLA Molecular Diagnostics Laboratories Page:3 Gene_Symbol Total_coding_bp %_bp_>=10X Associated_Disease(OMIM) ABCA3 5261 99% ABCA3‐Related Pulmonary Surfactant Metabolism Dysfunction ABCA3 5261 99% Pulmonary Surfactant Metabolism Dysfunction ABCA4 7022 100% ABCA4‐Related Retinitis Pigmentosa ABCA4 7022 100% ABCA4‐Related Stargardt Disease 1 ABCA4 7022 100% Age‐Related Macular Degeneration ABCA4 7022 100% Age‐Related Macular Degeneration 2 ABCA4 7022 100% Cone‐Rod Dystrophy 3 ABCA4 7022 100% Retinitis Pigmentosa, Autosomal Recessive ABCA4 7022 100% Stargardt Disease, Autosomal Recessive ABCA5 5084 100% . ABCA6 5104 100% . ABCA7 6709 96% . ABCA8 4894 100% . ABCA9 5066 100% . ABCB1 3951 100% . ABCB10 2269 77% . ABCB11 4074 100% ABCB11‐Related Intrahepatic Cholestasis ABCB11 4074 100% Low Gamma‐GT Familial Intrahepatic Cholestasis ABCB4 3969 100% Progressive Familial Intrahepatic Cholestasis 3 ABCB5 3923 100% . ABCB6 2605 100% . ABCB7 2332 100% X‐Linked Sideroblastic Anemia and Ataxia ABCB8 2221 100% . ABCB9 2551 90% . ABCC1 4720 98% . ABCC10 4655 100% . ABCC11 4265 100% . ABCC12 4200 100% . ABCC2 4781 100% Dubin‐Johnson Syndrome ABCC3 4994 99% . ABCC4 4151 99% . ABCC5 4575 100% . UCLA Health System Clinical Exome Sequencing Enhanced Package Department of Pathology and Laboratory Medicine Feb 2012 UCLA Molecular Diagnostics Laboratories Page:4 Gene_Symbol Total_coding_bp %_bp_>=10X Associated_Disease(OMIM) ABCC6 4646 92% Pseudoxanthoma Elasticum ABCC8 4947 97% ABCC8‐Related Hyperinsulinism ABCC8 4947 97% ABCC8‐Related Permanent Neonatal Diabetes Mellitus ABCC8 4947 97% ABCC8‐Related Transient Neonatal Diabetes Mellitus 2 ABCC8 4947 97% Familial Hyperinsulinism ABCC8 4947 97% Permanent Neonatal Diabetes Mellitus ABCC9 4944 100% ABCC9‐Related Dilated Cardiomyopathy ABCC9 4944 100% Dilated Cardiomyopathy ABCD1 2436 92% Adrenoleukodystrophy, X‐Linked ABCD2 2263 100% . ABCD3 2103 100% . ABCD4 1897 100% . ABCE1 1868 100% . ABCF1 2795 94% . ABCF2 1969 100% . ABCF3 2214 100% . ABCG1 2265 95% . ABCG2 2047 100% . ABCG4 1997 100% . ABCG5 2008 91% Sitosterolemia ABCG8 2074 97% Sitosterolemia ABHD1 1278 100% . ABHD10 941 100% . ABHD11 1078 99% . ABHD12 1311 85% Polyneuropathy, Hearing Loss, Ataxia, Retinitis Pigmentosa, and Cataract ABHD12B 1141 91% . ABHD13 1018 100% . ABHD14A 836 91% . ABHD14B 907 98% . ABHD15 1415 88% . ABHD16A 2173 94% . ABHD16B 1414 66% . UCLA Health System Clinical Exome Sequencing Enhanced Package Department of Pathology and Laboratory Medicine Feb 2012 UCLA Molecular Diagnostics Laboratories Page:5 Gene_Symbol Total_coding_bp %_bp_>=10X Associated_Disease(OMIM) ABHD2 1314 100% . ABHD3 1266 100% . ABHD4 1057 98% . ABHD5 1097 100% Chanarin‐Dorfman Syndrome ABHD6 1046 100% . ABHD8 1336 100% . ABI1 1630 97% . ABI2 1470 100% . ABI3 1133 89% . ABI3BP 3424 100% . ABL1 3577 99% . ABL2 3827 99% . ABLIM1 2586 100% . ABLIM2 2076 99% . ABLIM3 2144 100% . ABO 7 0% . ABP1 2329 100% . ABR 2811 97% . ABRA 1154 100% . ABT1 831 100% . ABTB1 1485 97% . ABTB2 3146 90% . ACAA1 1324 93% . ACAA2 1240 92% . ACACA 7433 100% . ACACB 7670 100% . ACAD10 3357 97% . ACAD11 2440 100% . ACAD8 1292 97% Isobutyryl‐CoA Dehydrogenase Deficiency ACAD9 2330 100% Acyl‐CoA Dehydrogenase 9 Deficiency ACADL 1337 96% Long‐Chain Acyl‐CoA Dehydrogenase Deficiency ACADM 1326 100% Medium Chain Acyl‐Coenzyme A Dehydrogenase Deficiency UCLA Health System Clinical Exome Sequencing Enhanced Package Department of Pathology and Laboratory Medicine Feb 2012 UCLA Molecular Diagnostics Laboratories Page:6 Gene_Symbol Total_coding_bp %_bp_>=10X Associated_Disease(OMIM) ACADS 1279 96% Short Chain Acyl‐CoA Dehydrogenase Deficiency ACADSB 1343 97% Acyl‐CoA Dehydrogenase, Short/Branched Chain Deficiency ACADVL 2186 98% Very Long Chain Acyl‐Coenzyme A Dehydrogenase Deficiency ACAN 7661 87% . ACAP1 2311 95% . ACAP2 2429 98% . ACAP3 2601 82% . ACAT1 1332 94% Ketothiolase Deficiency ACAT2 1230 99% . ACBD3 1619 86% . ACBD4 1094 97% . ACBD5 1670 100% . ACBD6 881 100% . ACBD7 283 100% . ACCN1 2291 93% . ACCN2 1769 100% . ACCN3 1755 97% . ACCN4 2041 94% . ACCN5 1558 100% . ACCS 1562 100% . ACCSL 1763 100% . ACD 1842 100% . ACE 4224 95% Cardiovascular Disease Risk Factor (Angiotensin Converting Enzyme (ACE)) ACE2 2490 100% . ACER1 819 100% . ACER2 852 95% . ACER3 848 88% . ACHE 2171 98% . ACIN1 4249 100% . ACLY 3445 100% . ACMSD 1051 100% . ACN9 386 100% . UCLA Health System Clinical Exome Sequencing Enhanced Package Department of Pathology and Laboratory Medicine Feb 2012 UCLA Molecular Diagnostics Laboratories Page:7 Gene_Symbol Total_coding_bp %_bp_>=10X Associated_Disease(OMIM) ACO1 2772 100% . ACO2 2496 100% . ACOT1 1278 73% . ACOT11 2052 96% . ACOT12 1736 94% . ACOT13 436 100% . ACOT2 1464 96% . ACOT4 1278 91% . ACOT6 632 100% . ACOT7 1437 94% . ACOT8 984 100% . ACOT9 1434 99% . ACOX1 2204 100% Pseudoneonatal Adrenoleukodystrophy ACOX2 2129 100% . ACOX3 2171 94% . ACOXL 1811 99% . ACP1 683 100% . ACP2 1349 100% . ACP5 994 100% . ACP6 1327 98% . ACPL2 1464 100% . ACPP 1324 100% . ACPT 1325 86% . ACR 1286 90% . ACRBP 1672 98% . ACRC 2124 97% . ACRV1 814 100% . ACSBG1 2231 100% . ACSBG2 2053 100% . ACSF2 1912 96% . ACSF3 1820 99% . ACSL1 2216 100% . UCLA Health System Clinical Exome Sequencing Enhanced Package Department of Pathology and Laboratory Medicine Feb 2012 UCLA Molecular Diagnostics Laboratories Page:8 Gene_Symbol Total_coding_bp %_bp_>=10X Associated_Disease(OMIM) ACSL3 2219 100% . ACSL4 2192 100% X‐Linked Mental Retardation 63 ACSL5 2304 100% . ACSL6 2346 100% . ACSM1 1800 100% . ACSM2A 1787 100% . ACSM2B 1786 100% . ACSM3 1978 100% . ACSM4 1795 100% . ACSM5 1792 100% . ACSS1 2128 96% . ACSS2 2227 93% . ACSS3 2125 99% . ACTA1 1158 100% ACTA1‐Related Congenital Fiber‐Type Disproportion ACTA1 1158 100% ACTA1‐Related Nemaline Myopathy ACTA1 1158 100% Childhood Restrictive Cardiomyopathy ACTA1 1158 100% Congenital Fiber‐Type Disproportion ACTA1 1158 100% Nemaline Myopathy ACTA2 1166 100% ACTA2‐Related Thoracic Aortic Aneurysms and Aortic Dissections ACTA2 1166 100% Thoracic Aortic Aneurysms and Aortic Dissections ACTB 1154 100% . ACTBL2 1135 100% . ACTC1 1158 100% ACTC1‐Related Dilated Cardiomyopathy ACTC1 1158 100% ACTC1‐Related Familial Hypertrophic Cardiomyopathy ACTC1 1158 100% Atrial Septal Defect 5 ACTC1 1158 100% Dilated Cardiomyopathy ACTC1 1158 100% Familial Hypertrophic Cardiomyopathy ACTG1 1148 100% DFNA20/26 Nonsyndromic Hearing Loss and Deafness ACTG1 1148 100% Nonsyndromic Hearing Loss and Deafness, Autosomal Dominant ACTG2 1264 100% . ACTL10 742 92% . ACTL6A 1355 100% . UCLA Health System Clinical Exome Sequencing Enhanced Package Department of Pathology and Laboratory Medicine Feb 2012 UCLA Molecular Diagnostics Laboratories Page:9 Gene_Symbol Total_coding_bp %_bp_>=10X Associated_Disease(OMIM) ACTL6B 1337 96% . ACTL7A 1312 100% . ACTL7B 1252 100% . ACTL8 1109 100% . ACTL9 1255 100% . ACTN1 2962 100% . ACTN2 2769 100% ACTN2‐Related Dilated Cardiomyopathy ACTN2 2769 100% ACTN2‐Related Familial Hypertrophic Cardiomyopathy ACTN2 2769 100% Dilated Cardiomyopathy ACTN2 2769 100% Familial Hypertrophic Cardiomyopathy ACTN3 2790 99% . ACTN4 2820 96% Focal Segmental Glomerulosclerosis ACTN4 2820 96% Focal Segmental Glomerulosclerosis 1 ACTR10 1306 100% . ACTR1A 1175 100% . ACTR1B 1179 97% . ACTR2 1240 99% . ACTR3 1305 97% . ACTR3B 1305 96% . ACTR3C 708 100% . ACTR5 1860 88% . ACTR6 1408 100% . ACTR8 1946 100% . ACTRT1 1135 100% . ACTRT2 1138 100% . ACVR1 1566 100% Fibrodysplasia
Load more

Recommended publications
  • Targeted Sequence Capture and High-Throughput Sequencing in the Molecular Diagnosis of Ichthyosis and Other Skin Diseases
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE providedCA by Elsevier Scott - Publisheret al. Connector Sequence Capture in Molecular Diagnosis of Skin Diseases Immunohistochemical staining indi- 1The Wellcome Trust Center for Human cause of Olmsted syndrome. Am J Hum cated that MBTPS2 is mainly expressed Genetics, Nuffield Department of Clinical Genet 90:558–64 Medicine, University of Oxford, Oxford, UK; Mevorah B, Goldberg I, Sprecher E et al. (2005) in the upper granular layer in normal 2 Centre for Cutaneous Research, The Blizard Olmsted syndrome: mutilating palmo- skin, as previously shown (Aten et al., Institute, Barts & The London School of plantar keratoderma with periorificial 2010); however, in OS skin, MBTPS2 Medicine and Dentistry, Queen Mary keratotic plaques. J Am Acad Dermatol 53: University of London, London, UK; S266–72 was expressed throughout the epi- 3 dermis (Figure 2c). There was no Department of Dermatology, Jundishapur Naiki M, Mizuno S, Yamada K et al. (2012) University of Medical Sciences, Ahvaz, Iran; MBTPS2 mutation causes BRESEK/BRESHECK 4 apparent difference in MBTPS2 locali- Genetic Department, Kerman University of syndrome. Am J Med Genet A 158A:97–102 zation in the skin of a KFSD patient with 5 Medical Sciences, Kerman, Iran and Darwin Oeffner F, Fischer G, Happle R et al. (2009) IFAP the p.N508S mutation (Aten et al., Building, University College London Genetics syndrome is caused by deficiency in MBTPS2, 2010). It is unclear why this is but it Institute, University College London, London, an intramembrane zinc metalloprotease essen- may be because of differences in UK tial for cholesterol homeostasis and ER stress E-mail: [email protected] response.
    [Show full text]
  • Supplemental Figure 1. Vimentin
    Double mutant specific genes Transcript gene_assignment Gene Symbol RefSeq FDR Fold- FDR Fold- FDR Fold- ID (single vs. Change (double Change (double Change wt) (single vs. wt) (double vs. single) (double vs. wt) vs. wt) vs. single) 10485013 BC085239 // 1110051M20Rik // RIKEN cDNA 1110051M20 gene // 2 E1 // 228356 /// NM 1110051M20Ri BC085239 0.164013 -1.38517 0.0345128 -2.24228 0.154535 -1.61877 k 10358717 NM_197990 // 1700025G04Rik // RIKEN cDNA 1700025G04 gene // 1 G2 // 69399 /// BC 1700025G04Rik NM_197990 0.142593 -1.37878 0.0212926 -3.13385 0.093068 -2.27291 10358713 NM_197990 // 1700025G04Rik // RIKEN cDNA 1700025G04 gene // 1 G2 // 69399 1700025G04Rik NM_197990 0.0655213 -1.71563 0.0222468 -2.32498 0.166843 -1.35517 10481312 NM_027283 // 1700026L06Rik // RIKEN cDNA 1700026L06 gene // 2 A3 // 69987 /// EN 1700026L06Rik NM_027283 0.0503754 -1.46385 0.0140999 -2.19537 0.0825609 -1.49972 10351465 BC150846 // 1700084C01Rik // RIKEN cDNA 1700084C01 gene // 1 H3 // 78465 /// NM_ 1700084C01Rik BC150846 0.107391 -1.5916 0.0385418 -2.05801 0.295457 -1.29305 10569654 AK007416 // 1810010D01Rik // RIKEN cDNA 1810010D01 gene // 7 F5 // 381935 /// XR 1810010D01Rik AK007416 0.145576 1.69432 0.0476957 2.51662 0.288571 1.48533 10508883 NM_001083916 // 1810019J16Rik // RIKEN cDNA 1810019J16 gene // 4 D2.3 // 69073 / 1810019J16Rik NM_001083916 0.0533206 1.57139 0.0145433 2.56417 0.0836674 1.63179 10585282 ENSMUST00000050829 // 2010007H06Rik // RIKEN cDNA 2010007H06 gene // --- // 6984 2010007H06Rik ENSMUST00000050829 0.129914 -1.71998 0.0434862 -2.51672
    [Show full text]
  • Implications in Parkinson's Disease
    Journal of Clinical Medicine Review Lysosomal Ceramide Metabolism Disorders: Implications in Parkinson’s Disease Silvia Paciotti 1,2 , Elisabetta Albi 3 , Lucilla Parnetti 1 and Tommaso Beccari 3,* 1 Laboratory of Clinical Neurochemistry, Department of Medicine, University of Perugia, Sant’Andrea delle Fratte, 06132 Perugia, Italy; [email protected] (S.P.); [email protected] (L.P.) 2 Section of Physiology and Biochemistry, Department of Experimental Medicine, University of Perugia, Sant’Andrea delle Fratte, 06132 Perugia, Italy 3 Department of Pharmaceutical Sciences, University of Perugia, Via Fabretti, 06123 Perugia, Italy; [email protected] * Correspondence: [email protected] Received: 29 January 2020; Accepted: 20 February 2020; Published: 21 February 2020 Abstract: Ceramides are a family of bioactive lipids belonging to the class of sphingolipids. Sphingolipidoses are a group of inherited genetic diseases characterized by the unmetabolized sphingolipids and the consequent reduction of ceramide pool in lysosomes. Sphingolipidoses include several disorders as Sandhoff disease, Fabry disease, Gaucher disease, metachromatic leukodystrophy, Krabbe disease, Niemann Pick disease, Farber disease, and GM2 gangliosidosis. In sphingolipidosis, lysosomal lipid storage occurs in both the central nervous system and visceral tissues, and central nervous system pathology is a common hallmark for all of them. Parkinson’s disease, the most common neurodegenerative movement disorder, is characterized by the accumulation and aggregation of misfolded α-synuclein that seem associated to some lysosomal disorders, in particular Gaucher disease. This review provides evidence into the role of ceramide metabolism in the pathophysiology of lysosomes, highlighting the more recent findings on its involvement in Parkinson’s disease. Keywords: ceramide metabolism; Parkinson’s disease; α-synuclein; GBA; GLA; HEX A-B; GALC; ASAH1; SMPD1; ARSA * Correspondence [email protected] 1.
    [Show full text]
  • Constitutive Activation of RAS/MAPK Pathway Cooperates with Trisomy 21 and Is Therapeutically Exploitable in Down Syndrome B-Cell Leukemia
    Author Manuscript Published OnlineFirst on March 27, 2020; DOI: 10.1158/1078-0432.CCR-19-3519 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Constitutive activation of RAS/MAPK pathway cooperates with trisomy 21 and is therapeutically exploitable in Down syndrome B-cell Leukemia Anouchka P. Laurent1,2, Aurélie Siret1, Cathy Ignacimouttou1, Kunjal Panchal3, M’Boyba K. Diop4, Silvia Jenny5, Yi-Chien Tsai5, Damien Ross-Weil1, Zakia Aid1, Naïs Prade6, Stéphanie Lagarde6, Damien Plassard7, Gaelle Pierron8, Estelle Daudigeos-Dubus4, Yann Lecluse4, Nathalie Droin1, Beat Bornhauser5, Laurence C. Cheung3,9, John D. Crispino10, Muriel Gaudry1, Olivier A. Bernard1, Elizabeth Macintyre11, Carole Barin Bonnigal12, Rishi S. Kotecha3,9,13, Birgit Geoerger4, Paola Ballerini14, Jean-Pierre Bourquin5, Eric Delabesse6, Thomas Mercher1,15 and Sébastien Malinge1,3 1INSERM U1170, Gustave Roussy Institute, Université Paris Saclay, Villejuif, France 2Université Paris Diderot, Paris, France 3Telethon Kids Cancer Centre, Telethon Kids Institute, University of Western Australia, Perth, Australia 4Gustave Roussy Institute Cancer Campus, Department of Pediatric and Adolescent Oncology, INSERM U1015, Equipe Labellisée Ligue Nationale contre le Cancer, Université Paris-Saclay, Villejuif, France 5Department of Pediatric Oncology, Children’s Research Centre, University Children’s Hospital Zurich, Zurich, Switzerland 6Centre of Research on Cancer of Toulouse (CRCT), CHU Toulouse, Université Toulouse III, Toulouse, France 7IGBMC, Plateforme GenomEast, UMR7104 CNRS, Ilkirch, France 8Service de Génétique, Institut Curie, Paris, France 9School of Pharmacy and Biomedical Sciences, Curtin University, Bentley, Australia 10Division of Hematology/Oncology, Northwestern University, Chicago, USA 11Hematology, Université de Paris, Institut Necker-Enfants Malades and Assistance Publique – Hopitaux de Paris, Paris, France 12Centre Hospitalier Universitaire de Tours, Tours, France 1 Downloaded from clincancerres.aacrjournals.org on September 30, 2021.
    [Show full text]
  • Acetyl-Coa Synthetase 3 Promotes Bladder Cancer Cell Growth Under Metabolic Stress Jianhao Zhang1, Hongjian Duan1, Zhipeng Feng1,Xinweihan1 and Chaohui Gu2
    Zhang et al. Oncogenesis (2020) 9:46 https://doi.org/10.1038/s41389-020-0230-3 Oncogenesis ARTICLE Open Access Acetyl-CoA synthetase 3 promotes bladder cancer cell growth under metabolic stress Jianhao Zhang1, Hongjian Duan1, Zhipeng Feng1,XinweiHan1 and Chaohui Gu2 Abstract Cancer cells adapt to nutrient-deprived tumor microenvironment during progression via regulating the level and function of metabolic enzymes. Acetyl-coenzyme A (AcCoA) is a key metabolic intermediate that is crucial for cancer cell metabolism, especially under metabolic stress. It is of special significance to decipher the role acetyl-CoA synthetase short chain family (ACSS) in cancer cells confronting metabolic stress. Here we analyzed the generation of lipogenic AcCoA in bladder cancer cells under metabolic stress and found that in bladder urothelial carcinoma (BLCA) cells, the proportion of lipogenic AcCoA generated from glucose were largely reduced under metabolic stress. Our results revealed that ACSS3 was responsible for lipogenic AcCoA synthesis in BLCA cells under metabolic stress. Interestingly, we found that ACSS3 was required for acetate utilization and histone acetylation. Moreover, our data illustrated that ACSS3 promoted BLCA cell growth. In addition, through analyzing clinical samples, we found that both mRNA and protein levels of ACSS3 were dramatically upregulated in BLCA samples in comparison with adjacent controls and BLCA patients with lower ACSS3 expression were entitled with longer overall survival. Our data revealed an oncogenic role of ACSS3 via regulating AcCoA generation in BLCA and provided a promising target in metabolic pathway for BLCA treatment. 1234567890():,; 1234567890():,; 1234567890():,; 1234567890():,; Introduction acetyl-CoA synthetase short chain family (ACSS), which In cancer cells, considerable number of metabolic ligates acetate and CoA6.
    [Show full text]
  • EXTENDED CARRIER SCREENING Peace of Mind for Planned Pregnancies
    Focusing on Personalised Medicine EXTENDED CARRIER SCREENING Peace of Mind for Planned Pregnancies Extended carrier screening is an important tool for prospective parents to help them determine their risk of having a child affected with a heritable disease. In many cases, parents aren’t aware they are carriers and have no family history due to the rarity of some diseases in the general population. What is covered by the screening? Genomics For Life offers a comprehensive Extended Carrier Screening test, providing prospective parents with the information they require when planning their pregnancy. Extended Carrier Screening has been shown to detect carriers who would not have been considered candidates for traditional risk- based screening. With a simple mouth swab collection, we are able to test for over 419 genes associated with inherited diseases, including Fragile X Syndrome, Cystic Fibrosis and Spinal Muscular Atrophy. The assay has been developed in conjunction with clinical molecular geneticists, and includes genes listed in the NIH Genetic Test Registry. For a list of genes and disorders covered, please see the reverse of this brochure. If your gene of interest is not covered on our Extended Carrier Screening panel, please contact our friendly team to assist you in finding a gene test panel that suits your needs. Why have Extended Carrier Screening? Extended Carrier Screening prior to pregnancy enables couples to learn about their reproductive risk and consider a complete range of reproductive options, including whether or not to become pregnant, whether to use advanced reproductive technologies, such as preimplantation genetic diagnosis, or to use donor gametes.
    [Show full text]
  • The Molecular Karyotype of 25 Clinical-Grade Human Embryonic Stem Cell Lines Received: 07 August 2015 1 1 2 3,4 Accepted: 27 October 2015 Maurice A
    www.nature.com/scientificreports OPEN The Molecular Karyotype of 25 Clinical-Grade Human Embryonic Stem Cell Lines Received: 07 August 2015 1 1 2 3,4 Accepted: 27 October 2015 Maurice A. Canham , Amy Van Deusen , Daniel R. Brison , Paul A. De Sousa , 3 5 6 5 7 Published: 26 November 2015 Janet Downie , Liani Devito , Zoe A. Hewitt , Dusko Ilic , Susan J. Kimber , Harry D. Moore6, Helen Murray3 & Tilo Kunath1 The application of human embryonic stem cell (hESC) derivatives to regenerative medicine is now becoming a reality. Although the vast majority of hESC lines have been derived for research purposes only, about 50 lines have been established under Good Manufacturing Practice (GMP) conditions. Cell types differentiated from these designated lines may be used as a cell therapy to treat macular degeneration, Parkinson’s, Huntington’s, diabetes, osteoarthritis and other degenerative conditions. It is essential to know the genetic stability of the hESC lines before progressing to clinical trials. We evaluated the molecular karyotype of 25 clinical-grade hESC lines by whole-genome single nucleotide polymorphism (SNP) array analysis. A total of 15 unique copy number variations (CNVs) greater than 100 kb were detected, most of which were found to be naturally occurring in the human population and none were associated with culture adaptation. In addition, three copy-neutral loss of heterozygosity (CN-LOH) regions greater than 1 Mb were observed and all were relatively small and interstitial suggesting they did not arise in culture. The large number of available clinical-grade hESC lines with defined molecular karyotypes provides a substantial starting platform from which the development of pre-clinical and clinical trials in regenerative medicine can be realised.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Understanding the Molecular Pathobiology of Acid Ceramidase Deficiency
    Understanding the Molecular Pathobiology of Acid Ceramidase Deficiency By Fabian Yu A thesis submitted in conformity with the requirements for the degree of Doctor of Philosophy Institute of Medical Science University of Toronto © Copyright by Fabian PS Yu 2018 Understanding the Molecular Pathobiology of Acid Ceramidase Deficiency Fabian Yu Doctor of Philosophy Institute of Medical Science University of Toronto 2018 Abstract Farber disease (FD) is a devastating Lysosomal Storage Disorder (LSD) caused by mutations in ASAH1, resulting in acid ceramidase (ACDase) deficiency. ACDase deficiency manifests along a broad spectrum but in its classical form patients die during early childhood. Due to the scarcity of cases FD has largely been understudied. To circumvent this, our lab previously generated a mouse model that recapitulates FD. In some case reports, patients have shown signs of visceral involvement, retinopathy and respiratory distress that may lead to death. Beyond superficial descriptions in case reports, there have been no in-depth studies performed to address these conditions. To improve the understanding of FD and gain insights for evaluating future therapies, we performed comprehensive studies on the ACDase deficient mouse. In the visual system, we reported presence of progressive uveitis. Further tests revealed cellular infiltration, lipid buildup and extensive retinal pathology. Mice developed retinal dysplasia, impaired retinal response and decreased visual acuity. Within the pulmonary system, lung function tests revealed a decrease in lung compliance. Mice developed chronic lung injury that was contributed by cellular recruitment, and vascular leakage. Additionally, we report impairment to lipid homeostasis in the lungs. ii To understand the liver involvement in FD, we characterized the pathology and performed transcriptome analysis to identify gene and pathway changes.
    [Show full text]
  • ABCB7 Gene ATP Binding Cassette Subfamily B Member 7
    ABCB7 gene ATP binding cassette subfamily B member 7 Normal Function The ABCB7 gene provides instructions for making a protein known as an ATP-binding cassette (ABC) transporter. ABC transporter proteins carry many types of molecules across membranes in cells. The ABCB7 protein is located in the inner membrane of cell structures called mitochondria. Mitochondria are involved in a wide variety of cellular activities, including energy production, chemical signaling, and regulation of cell growth and division. In the mitochondria of developing red blood cells (erythroblasts), the ABCB7 protein plays a critical role in the production of heme. Heme contains iron and is a component of hemoglobin, the protein that carries oxygen in the blood. The ABCB7 protein is also involved in the formation of certain proteins containing clusters of iron and sulfur atoms (Fe-S clusters). Researchers suspect that the ABCB7 protein transports Fe-S clusters from mitochondria, where they are formed, to the surrounding cellular fluid (cytosol), where they can be incorporated into proteins. Overall, researchers believe that the ABCB7 protein helps maintain an appropriate balance of iron (iron homeostasis) in developing red blood cells. Health Conditions Related to Genetic Changes X-linked sideroblastic anemia and ataxia At least three mutations in the ABCB7 gene have been identified in people with X-linked sideroblastic anemia with ataxia. Each of these mutations changes a single protein building block (amino acid) in the ABCB7 protein, slightly altering its structure. These changes disrupt the protein's usual role in heme production and iron homeostasis. Anemia results when heme cannot be produced normally, and therefore not enough hemoglobin is made.
    [Show full text]
  • Structures and Functions of Mitochondrial ABC Transporters
    ATP-binding cassette transporters: from mechanism to organism 943 Structures and functions of mitochondrial ABC transporters Theresia A. Schaedler*, Belinda Faust†, Chitra A. Shintre†, Elisabeth P. Carpenter†, Vasundara Srinivasan‡, Hendrik W. van Veen§ and Janneke Balk1 *Department of Biological Chemistry and Crop Protection, Rothamsted Research, West Common, Harpenden, AL5 2JQ, U.K. †Structural Genomics Consortium, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, OX3 7DQ, U.K. ‡LOEWE center for synthetic microbiology (SYNMIKRO) and Philipps University, D-35043 Marburg, Germany §Department of Pharmacology, University of Cambridge, Tennis Court Road, Cambridge, CB2 1PD, U.K. John Innes Centre and University of East Anglia, Colney Lane, Norwich, NR4 7UH, U.K. Abstract A small number of physiologically important ATP-binding cassette (ABC) transporters are found in mitochondria. Most are half transporters of the B group forming homodimers and their topology suggests they function as exporters. The results of mutant studies point towards involvement in iron cofactor biosynthesis. In particular, ABC subfamily B member 7 (ABCB7) and its homologues in yeast and plants are required for iron-sulfur (Fe-S) cluster biosynthesis outside of the mitochondria, whereas ABCB10 is involved in haem biosynthesis. They also play a role in preventing oxidative stress. Mutations in ABCB6 and ABCB7 have been linked to human disease. Recent crystal structures of yeast Atm1 and human ABCB10 have been key to identifying substrate-binding sites and transport mechanisms. Combined with in vitro and in vivo studies, progress is being made to find the physiological substrates of the different mitochondrial ABC transporters. Sequence analysis of mitochondrial ABC The ABCB7 group, which includes the ABC transporters transporters of the mitochondria Atm1 in yeast and ATM3 in Arabidopsis, Mitochondria of most eukaryote species harbour 2–4 can be found in virtually all eukaryotic species.
    [Show full text]
  • Type of the Paper (Article
    Supplementary Material A Proteomics Study on the Mechanism of Nutmeg-induced Hepatotoxicity Wei Xia 1, †, Zhipeng Cao 1, †, Xiaoyu Zhang 1 and Lina Gao 1,* 1 School of Forensic Medicine, China Medical University, Shenyang 110122, P. R. China; lessen- [email protected] (W.X.); [email protected] (Z.C.); [email protected] (X.Z.) † The authors contributed equally to this work. * Correspondence: [email protected] Figure S1. Table S1. Peptide fraction separation liquid chromatography elution gradient table. Time (min) Flow rate (mL/min) Mobile phase A (%) Mobile phase B (%) 0 1 97 3 10 1 95 5 30 1 80 20 48 1 60 40 50 1 50 50 53 1 30 70 54 1 0 100 1 Table 2. Liquid chromatography elution gradient table. Time (min) Flow rate (nL/min) Mobile phase A (%) Mobile phase B (%) 0 600 94 6 2 600 83 17 82 600 60 40 84 600 50 50 85 600 45 55 90 600 0 100 Table S3. The analysis parameter of Proteome Discoverer 2.2. Item Value Type of Quantification Reporter Quantification (TMT) Enzyme Trypsin Max.Missed Cleavage Sites 2 Precursor Mass Tolerance 10 ppm Fragment Mass Tolerance 0.02 Da Dynamic Modification Oxidation/+15.995 Da (M) and TMT /+229.163 Da (K,Y) N-Terminal Modification Acetyl/+42.011 Da (N-Terminal) and TMT /+229.163 Da (N-Terminal) Static Modification Carbamidomethyl/+57.021 Da (C) 2 Table S4. The DEPs between the low-dose group and the control group. Protein Gene Fold Change P value Trend mRNA H2-K1 0.380 0.010 down Glutamine synthetase 0.426 0.022 down Annexin Anxa6 0.447 0.032 down mRNA H2-D1 0.467 0.002 down Ribokinase Rbks 0.487 0.000
    [Show full text]